Loading institutional data...
Loading institutional data...
Held by 237 of 5,944 reporting institutions (93th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $34.55 today, the market must believe free cash flow compounds -4.5%/yr for a decade (off $247M normalized FCF).
The market's -4.5% is more conservative than its 9-yr track record.
2-stage DCF · 0.04B shares · net debt $733M
mean 17.2% · volatility σ 50% · implied rate exceeded in 7/9 yrs
Central path = implied -4.5%/yr growth; shaded band = ±1σ (50%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| AMN | $1.3B | — | 20.4× | 0.5× | -8.5% | 28.3% | -3.5% | -14.9% | -6.8% | 7.6× | 237 |
Peers = companies sharing AMN's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.73B 100.0% | $2.98B 100.0% | $3.79B 100.0% | $5.24B 100.0% | $3.98B 100.0% | $2.39B 100.0% | $2.22B 100.0% | $2.14B 100.0% | $1.99B 100.0% | $1.90B 100.0% |
| Cost of Revenue | $1.96B 71.7% | $2.06B 69.2% | $2.54B 67.0% | $3.53B 67.3% | $2.67B 67.1% | $1.60B 66.9% | $1.48B 66.5% | $1.44B 67.4% | $1.34B 67.6% | $1.28B 67.4% |
| Gross Profit | $774.1M 28.3% | $919.4M 30.8% | $1.25B 33.0% | $1.72B 32.7% | $1.31B 32.9% | $791.8M 33.1% | $743.5M 33.5% | $696.4M 32.6% | $644.4M 32.4% | $619.7M 32.6% |
| Selling, General & Admin | $593.0M 21.7% | $632.5M 21.2% | $748.4M 19.8% | $936.6M 17.9% | $730.5M 18.3% | $549.7M 23.0% | $508.0M 22.9% | $452.3M 21.2% | $399.7M 20.1% | $398.5M 20.9% |
| Total Operating Expenses | $829.5M 30.4% | $1.02B 34.3% | $911.2M 24.0% | $1.07B 20.4% | $831.6M 20.9% | $642.5M 26.8% | $566.5M 25.5% | $493.6M 23.1% | $432.0M 21.7% | $428.1M 22.5% |
| Operating Income | -$55.5M -2.0% | -$102.7M -3.4% | $338.4M 8.9% | $647.1M 12.3% | $478.0M 12.0% | $149.3M 6.2% | $176.9M 8.0% | $202.8M 9.5% | $212.4M 10.7% | $191.6M 10.1% |
| Interest Expense | $45.6M 1.7% | $69.9M 2.3% | $54.1M 1.4% | $40.4M 0.8% | $34.1M 0.9% | $57.7M 2.4% | $28.4M 1.3% | $16.1M 0.8% | $19.7M 1.0% | $15.5M 0.8% |
| Pretax Income | -$101.1M -3.7% | -$172.6M -5.8% | $284.3M 7.5% | $606.7M 11.6% | $443.9M 11.1% | $91.5M 3.8% | $148.5M 6.7% | $186.7M 8.7% | $192.8M 9.7% | $176.2M 9.3% |
| Income Tax Expense | -$5.4M -0.2% | -$25.6M -0.9% | $73.6M 1.9% | $162.7M 3.1% | $116.5M 2.9% | $20.9M 0.9% | $34.5M 1.6% | $44.9M 2.1% | $60.2M 3.0% | $70.3M 3.7% |
| Net Income | -$95.7M -3.5% | -$147.0M -4.9% | $210.7M 5.6% | $444.1M 8.5% | $327.4M 8.2% | $70.7M 3.0% | $114.0M 5.1% | $141.7M 6.6% | $132.6M 6.7% | $105.8M 5.6% |
| Per Share | ||||||||||
| EPS (Basic) | $-2.48 | $-3.85 | $5.38 | $9.96 | $6.87 | $1.49 | $2.44 | $2.99 | $2.77 | $2.21 |
| EPS (Diluted) | $-2.48 | $-3.85 | $5.36 | $9.90 | $6.81 | $1.48 | $2.40 | $2.91 | $2.68 | $2.15 |
| Weighted Avg Shares (Basic) | 38.5M | 38.2M | 39.2M | 44.6M | 47.7M | 47.4M | 46.7M | 47.4M | 47.8M | 47.9M |
| Weighted Avg Shares (Diluted) | 38.5M | 38.2M | 39.3M | 44.9M | 48.0M | 47.7M | 47.6M | 48.7M | 49.4M | 49.3M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor; leverage falling year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on $234M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: -7%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $34M covers the $4M due within a year 9.1× over. Scheduled principal only (excludes interest & revolver draws). As of 2016-12-31 (10-K).
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Effective rate ~5.9% on $767M of debt.
Cash vs short-term debt unavailable.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-17
No standout strengths flagged.
Where each multiple sits in its own 14-yr range · 40th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 5.4× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 67.4 | 66.5 | 66.9 | 67.1 | 67.3 | 67.0 | 69.2 | 71.7 |
| Gross Profit | 32.6 | 33.5 | 33.1 | 32.9 | 32.7 | 33.0 | 30.8 | 28.3 |
| SG&A | 21.2 | 22.9 | 23.0 | 18.3 | 17.9 | 19.8 | 21.2 | 21.7 |
| Operating Income | 9.5 | 8.0 | 6.2 | 12.0 | 12.3 | 8.9 | -3.4 | -2.0 |
| Income Tax | 2.1 | 1.6 | 0.9 | 2.9 | 3.1 | 1.9 | -0.9 | -0.2 |
| Net Income | 6.6 | 5.1 | 3.0 | 8.2 | 8.5 | 5.6 | -4.9 | -3.5 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on AMN: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.